• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Cytokinetics cans lead drug after phase 3 ALS wipeout fiercebiotech
    November 22, 2017
    Researchers set out to learn whether tirasemtiv, a fast skeletal muscle troponin activator, could drive greater improvements on a measure of lung capacity than placebo over 24 weeks. Tirasemtiv failed to clear that bar.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service